Epstein walked away from it. And, well, it had to weigh on Thorpe.
Cotara Phase 3, round 1 ended in lawsuits and counter-suits between PP and Cancer Therapeutics. Great article, BTW:
Peregrine Shows Desperation in Dusting Off Ancient Brain Tumor Drug
BY Adam Feuerstein 12/05/12 - 04:25 PM EST |
Tustin, Calif. ( TheStreet) -- Peregrine Pharmaceuticals (PPHM_) is either desperate or stupid if blowing dust off the ancient Cotara brain tumor program is the company's next great idea.
The U.S. Food and Drug Administration agreed to a design for a phase III study of Cotara in patients with recurrent glioblastoma multiformae (GBM), Peregrine said Wednesday.
Of course, Peregrine made the same exact announcement in December 2001. Eleven years ago, Peregrine announced plans to start a phase III study of Cotara in GBM patients following a meeting with FDA.
The Cotara phase III study of 2001 never happened. In September and November 2002, Peregrine met with FDA again. This time, agency officials raised concerns about the planned Cotara phase III study and told the company additional information and Cotara clinical data would be required.
This is where Peregrine's Cotara program ran off the rails and why today's announcement about a new FDA agreement on a phase III study design is far less significant than the company claims.
Following the November 2002 meeting with FDA, Peregrine was forced to essentially re-start Cotara's clinical program from the beginning. Over a five-year period from 2005 through 2010, Peregrine conducted a phase I and phase II study of Cotara in order to 1) find an appropriate dose; and 2) to measure how much of the drug was being absorbed into brain tumors and where else in the body it might go.
Lawsuits and more stock issued.
Gaddy no longer a moderator? I don't go over there as of a couple of weeks ago. When Yahoo turns into a PTSC board, I'll stop coming here, too.
A little residual ooze this morning. Similar to finding a nasty moist, wet place when you reach for the toilet paper roll.
Do enough rat experiments, something good might happen.
WASHINGTON -- At a research lab at Duke University Department of Pharmacology in 1979, a group of scientists sparked a major breakthrough in infant care from a failed experiment on rats.
The path of the righteous man is beset on all sides by the iniquities of the selfish and the tyranny of evil men. Blessed is he who, in the name of charity and good will, shepherds the weak through the valley of the darkness. For he is truly his brother's keeper and the finder of lost children. And I will strike down upon thee with great vengeance and furious anger those who attempt to poison and destroy my brothers. And you will know I am the Lord when I lay my vengeance upon you.
Cloak is the Shepard.
I thought I heard King say he was working on partnering with collaborators. Maybe he meant French women with shaved heads. Don't know.
July 2008 – Present (6 years 3 months) Tustin
Oversee and directed all work required by Peregrine's $32M TMT (DTRA) government contract. Designed animal studies and directed work at BSL3 and BSL4 sub-contract facilities; working with Junin and Ebola viruses.
October 2001 – January 2006 (4 years 4 months) Tustin CA and Houston, TX
Oversaw the radio-labeling of our Cotara product at our CMO Iso-Tex. Responsible for overseeing day to day radio-labeling operations for our two radio-labeled Abs
LC - Do they prefer to partner the "dozens of collaborations", thereby helping Bavi to market?
Biopharmaceutical company Peregrine Pharmaceuticals Inc. in Tustin said Friday that it has agreed with Schering AG to transfer management of the development of its lymphoma drug Oncolym from the German company to Peregrine.
Peregrine said in a news release that it will reacquire worldwide marketing and distribution rights for the product, which is in clinical trials for the treatment of intermediate and high-grade non-Hodgkin's B-cell lymphoma.
The company said that the transfer was based on the needs of both Peregrine and Schering and that Peregrine doesn't expect to need significant additional funds to complete the clinical trials. It plans to work with Schering on a rapid transition.
Under the prior agreement with Schering, Peregrine was responsible for 20% of Schering's development costs as well as all drug-related costs, which totaled about $1.7 million since April 1999.
What definition of weak hands are you referring to - futures, forex, poker? Is there any other definition?